Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the study is to determine the concentration of anecortave acetate (15 or 30 mg versus placebo) that is safe and effective for the inhibition of the growth of blood vessels in the retina in patients with wet AMD.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Anecortave Acetate 30 | Experimental |
| |
| Anecortave Acetate 15 | Experimental |
| |
| Anecortave Acetate 3 | Experimental |
| |
| Anecortave Acetate Vehicle | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Anecortave acetate 30 mg | Drug | 0.5ml administered onto the sclera once every six months for 24 months |
|
| Measure | Description | Time Frame |
|---|---|---|
| Mean change in logMAR visual acuity at 12 months from baseline. | 12 months |
Not provided
Not provided
Inclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C418047 | anecortave acetate |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Anecortave Acetate 15 mg | Drug | 0.5ml administered onto the sclera once every six months for 24 months |
|
| Anecortave Acetate 3 mg | Drug | 0.5ml administered onto the sclera once every six months for 24 months |
|
| Anecortave Acetate Vehicle | Other | 0.5ml administered onto the sclera once every six months for 24 months |
|